Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 724.

https://doi.org/10.1182/blood.V130.Suppl_1.724.724

Published: 2017

Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Blood (2017) 130 (Supplement 1): 725.

https://doi.org/10.1182/blood.V130.Suppl_1.725.725

Published: 2017

Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood (2017) 130 (6): 722–731.

https://doi.org/10.1182/blood-2017-04-779405

Published: 2017

Includes: Supplemental data

Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD

Blood (2015) 126 (23): 2509.

https://doi.org/10.1182/blood.V126.23.2509.2509

Published: 2015

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Liu, Malia Prahl, Chris J Bowden, Scott Biller, Sam Agresta, MD, Hua Yang, PhD

Blood (2015) 126 (23): 1310.

https://doi.org/10.1182/blood.V126.23.1310.1310

Published: 2015

Journal Articles

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Kha Le, PhD, Marvin Cohen, Yue Chen, Hyeryun Kim, Bruce Silver, Sam Agresta, MD, Elizabeth Merica, Charles Kung, Penelope Kosinski, Lee Silverman, Scott Biller, Hua Yang, PhD

Blood (2015) 126 (23): 3336.

https://doi.org/10.1182/blood.V126.23.3336.3336

Published: 2015

Journal Articles

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

Ann Barbier, Bruce Silver, Elizabeth Merica, Marvin Cohen, Charles Kung, Hua Yang, PhD, Rachael F. Grace, MD, Bertil Glader, MD PhD, Sam Agresta, MD

Blood (2015) 126 (23): 4548.

https://doi.org/10.1182/blood.V126.23.4548.4548

Published: 2015

Journal Articles

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie Schalm, Kimberly Straley, Camelia Gliser, Hua Yang, Jeremy Travins, Stuart Murray, Marion Dorsch, Sam Agresta, David P. Schenkein, Scott A. Biller, Shinsan M. Su, Wei Liu, Katharine E. Yen

Blood (2015) 125 (2): 296–303.

https://doi.org/10.1182/blood-2013-10-533604

Published: 2015

Includes: Supplemental data

Journal Articles

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Erica Hansen, Cyril Quivoron, Kim Straley, René M Lemieux, Janeta Popovici-Muller, Hossein Sadrzadeh, Amir T Fathi, Camelia Gliser, Muriel David, Véronique Saada, Jean-Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard-Lacronique, Katharine Yen

Blood (2014) 124 (21): 3734.

https://doi.org/10.1182/blood.V124.21.3734.3734

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Cyril Quivoron, Muriel David, Kim Straley, Jeremy Travins, Hyeryun Kim, Yue Chen, Dongwei Zhu, Véronique Saada, Olivia Bawa, Paule Opolon, Mélanie Polrot, Jean-Baptiste Micol, Christophe Willekens, Olivier Bernard, Hua Yang, Sam Agresta, Stéphane de Botton, Katharine Yen, Virginie Penard-Lacronique

Blood (2014) 124 (21): 3735.

https://doi.org/10.1182/blood.V124.21.3735.3735

Published: 2014

Journal Articles

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

Bin Fan, Yue Chen, Fang Wang, Katharine Yen, Luke Utley, Caroline Almon, Scott Biller, Sam Agresta, Hua Yang

Blood (2014) 124 (21): 3737.

https://doi.org/10.1182/blood.V124.21.3737.3737

Published: 2014

Journal Articles

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Charles Kung, Collin Hill, Yue Chen, Abhishek Jha, Penelope Kosinski, Michelle Clasquin, Yaguang Si, Hyeryun Kim, Jeff Hixon, Lenny Dang, Sam Agresta, Lee Silverman, Hua Yang

Blood (2014) 124 (21): 4010.

https://doi.org/10.1182/blood.V124.21.4010.4010

Published: 2014

Journal Articles

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Hua Yang, Elizabeth Merica, Yue Chen, Marvin Cohen, Ronald Goldwater, Collin Hill, Hyeryun Kim, Penelope Kosinski, Charles Kung, Bruce Silver, Luke Utley, Sam Agresta

Blood (2014) 124 (21): 4007.

https://doi.org/10.1182/blood.V124.21.4007.4007

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Blood (2014) 124 (21): 115.

https://doi.org/10.1182/blood.V124.21.115.115

Published: 2014

Journal Articles

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

Blood (2014) 124 (21): 1045.

https://doi.org/10.1182/blood.V124.21.1045.1045

Published: 2014

NARROW

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only